Evidence check: tTG IgA in the context of sleep

The biomarker tTG IgA (tissue transglutaminase antibodies) is primarily used for diagnosing and monitoring celiac disease. A direct, evidence-based link between tTG IgA levels and sleep quality or sleep disorders is not established in the current literature. While some studies report sleep disturbances in untreated celiac disease—potentially due to nocturnal gastrointestinal symptoms—there are no robust data correlating tTG IgA titers with objective sleep measures (e.g., polysomnography). The evidence is therefore weak to unclear. No direct causal mechanism connecting tTG IgA to sleep regulation is known. In a consumer health test context, it must be clearly stated that tTG IgA is not a sleep biomarker and should not be used to assess sleep issues. Clinically relevant sleep problems warrant medical evaluation, possibly including celiac disease workup if other symptoms are present.